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Cardiac risk assessment by gated single-photon
emission computed tomography in
asymptomatic end-stage renal disease patients
at the start of dialysis
Jwa-Kyung Kim, MD, Sung Gyun Kim, MD, Hyung Jik Kim, MD, PhD,
and Young Rim Song, MD
Objectives. This study assessed the impact of cardiac risk assessment using gated single-
photon emission computed tomography (SPECT) on cardiac events in end-stage renal disease
(ESRD) patients.
Methods. We evaluated 215 asymptomatic patients who began dialysis between January
2005 and April 2009. Baseline electrocardiography and echocardiography were performed in
all the patients. The subjects were stratiﬁed into low- and high-risk groups according to the
baseline cardiac status, and gated SPECT was additionally recommended for the high-risk
patients.
Results. The study population consisted of 50 low- and 165 high-risk patients undergoing
SPECT. Among the high-risk patients, 75 (45.5%) showed perfusion defects on SPECT and
their overall cardiac-event rate per person-year of follow-up was 15.0%, signiﬁcantly higher
than 4.5% in high-risk group without perfusion defect and 1.2% in low-risk group. The
presence of perfusion defect was a signiﬁcant independent predictor of adverse cardiac events
[hazard ratio (HR) 2.11; 95% conﬁdence interval (CI) 1.05-4.24; P 5 .035]. When gated
SPECT was added to the clinical and the echocardiographic variables, the prognostic stratiﬁ-
cation signiﬁcantly improved (P < .001). However, coronary revascularization was not
associated with improved cardiac event-free survival (HR 0.62; 95% CI 0.26-1.52; P 5 .296).
Conclusions. Gated SPECT may provide additional prognostic information for cardiac risk
stratiﬁcation,particularlyamonghigh-riskpatientsstartingdialysis.(JNuclCardiol2012;19:438–47.)
Key Words: Cardiac outcome Æ end-stage renal disease Æ risk stratiﬁcation Æ single-photon
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INTRODUCTION
Cardiovasculardiseaseistheleadingcauseofdeathin
patients with end-stage renal disease (ESRD),
1 and nearly
20%ofthesemortalitiescanbeattributedtocoronaryartery
disease (CAD).
2,3 As a large number of ESRD patients are
asymptomaticdespitehavingsigniﬁcantCAD,cardiacrisk
assessment in these patients is an important issue. How-
ever, no accurate screening strategy is available for these
asymptomatic patients, although symptomatic high-risk
patients are generally screened for CAD. The National
KidneyFoundationadvisesroutineCADscreeningonlyin
high-risk renal transplant candidates, such as patients with
diabetes, patients with a prior history of ischemic heart
disease oranabnormalelectrocardiogram, orpatientsover
50 years of age.
4 There is insufﬁcient evidence to support
the beneﬁt of routine screening and treatment in asymp-
tomatic dialysis patients, regardless of their cardiac risk
status. In addition, the traditional clinical risk assessment
model using Framingham risk scores
5 has limited value in
dialysis patients, as it does not include renal function as a
signiﬁcant predictor for cardiovascular mortality.
6 There-
fore, global consensus on a screening strategy and an
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438effective risk stratiﬁcation method are needed in asymp-
tomatic hemodialysis patients.
Although coronary angiography (CAG) remains the
goldstandardforthedetectionofoccultCAD,itisdifﬁcult
touseCAGinasymptomaticindividualsowingtotherisks
associatedwithexposuretonephrotoxiccontrastagentsor
procedure-related complications. In contrast, single-pho-
ton emission computed tomography (SPECT) is a non-
invasive pharmacological stress test suitable for patients
who are unable to exercise or patients who display
abnormal baseline electrocardiography (ECG) such as
chronic kidney disease (CKD) and dialysis patients.
Since 2005, we have conducted an independent
CAD screening program to detect occult CAD in
asymptomatic ESRD patients at the start of dialysis.
Our previous data showed that the prevalence of CAD
was 27.4% in asymptomatic ESRD patients and that the
diagnostic accuracy of SPECT was acceptable.
7 Screen-
ing for the presence of signiﬁcant CAD may lead to the
identiﬁcation of patients whose prognosis could be
improved with medical therapy and/or coronary revas-
cularization. The purpose of this study was to evaluate
the prognostic value of the stress/rest gated SPECT
imaging analysis for baseline cardiac risk stratiﬁcation,
and to investigate the beneﬁt of coronary revasculariza-
tion in asymptomatic high-risk ESRD patients with
signiﬁcant coronary stenosis.
METHODS
Patients and Study design
We evaluated asymptomatic ESRD patients who began
dialysis between January 2005 and April 2009 at the Hallym
University Sacred Heart Hospital in Korea. This study was
designed such that baseline resting ECG and two-dimensional
(2D) echocardiography tests were performed in all the patients,
as recommended by the Kidney Disease Outcomes Quality
Initiative (KDOQI) guidelines.
4 Subjects with typical anginal
pain or anginal equivalents (n = 26) were not invited to
participate. Patients presenting with signiﬁcant volume over-
load (n = 16) and those with a total follow-up duration of
\6 months (n = 72) were also excluded (Figure 1). This
study was approved by the institutional ethics committee and
was conducted according to the Declaration of Helsinki.
Based on the results of initial screening tests, the patients
were classiﬁed into low- and high-risk groups. Patients in the
high-risk group were[50 years of age; had diabetes for more
than 10 years; had a prior history of CAD or an abnormal
electrocardiogram [excluding left ventricular (LV) hypertro-
phy and electrolyte imbalance], a decreased LV ejection
fraction (LVEF) of \40%, or a regional wall motion abnor-
mality (RWMA) on echocardiography; and had two or more
traditional CAD risk factors such as hypertension, dyslipide-
mia, smoking, LV hypertrophy, or family history of premature
CAD.
5 A stress/rest gated SPECT analysis was performed on
the high-risk patients, and after consultation with a cardiolo-
gist, CAG was further recommended for those displaying a
positive stress test on SPECT.
Diagnostic Work-up
When a patient was considered euvolemic, comprehen-
sive echocardiographic measurements were performed
following several sessions of dialysis. LVEF, LV RWMA,
and LV geometric pattern data were collected using 2D
echocardiography in M-mode with color Doppler. The LVEFs
were calculated from the apical four- and two-chamber views
using Simpson’s methods. Based on the LV mass index
(LVMI) (normal values [115 g/m
2 in men, [95 g/m
2 in
women) and relative wall thickness (RWT) (normal 0.42),
echocardiographic LV hypertrophy (LVH) was categorized
into four LV geometry groups: concentric hypertrophy
(increased LVMI and increased RWT), eccentric hypertrophy
(increased LVMI and normal RWT), concentric remodeling
(normal LVMI and increased RWT), and normal geometry
(normal LVMI and normal RWT).
Gated SPECT analyses were acquired using
99mTc-tetro-
fosmin (Myoview; Siemens Medical Systems, Inc., USA) and a
pharmacological vasodilator (adenosine, 0.14 mg  kg
-1 
min
-1) with a 1-day protocol. For stress and rest images, 30
and 10 mCi of
99mTc-tetrofosmin were administered, respec-
tively. Quantitative analyses of SPECT data were performed
with the SPECT software packages Quantitative Gated SPECT
(QGS) and 4DM-SPECT (4DM) by a standard processing
method.Areversibleperfusiondefectwasdeﬁnedasaperfusion
defect on stress images that partially or completely resolved on
rest images in two or more contiguous segments. A ﬁxed
perfusion defect was deﬁned as a perfusion defect on stress
imagesintwoormorecontiguoussegmentsthatpersistedonrest
images. The summed stress score (SSS) and summed rest score
(SRS)wereobtainedusing17-segmentdefectscoresgradedona
5-point scale, and the summed difference score (SDS) was
calculated as the difference between the SSS and SRS. The
severity of myocardial perfusion defects was graded as normal
(SSS\4),mild(SSS4-8),moderate(SSS9-13),andsevere(SSS
C14). An abnormal perfusion scan was taken to indicate the
presence of a perfusion defect or elevated SSS C4. One
experienced nuclear cardiologist in our institution, who was
unaware of the clinical data, reviewed the SPECT images.
Patient gender was revealed only on request.
CAD was considered to be present when any of the major
coronary arteries showed luminal diameter narrowing of C50%
(visual assessment). A reduction of\50% in luminal diameter
was regarded as insigniﬁcant CAD. CAG images were ana-
lyzed by two different readers who were blinded to the clinical
information, SPECT analysis results, and clinical outcomes.
Follow-Up and Endpoints
Patients were followed by periodic examinations in an
outpatient setting. For patients not followed at our center,
information was obtained during telephone interviews. For
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Society of Nephrology Demographic Registry was queried.
The end of follow-up was determined by a cardiac event, or by
the last patient contact in the hospital for those without events.
Cardiac events were deﬁned as cardiac death, non-fatal acute
coronary syndrome (ACS), and acute decompensated heart
failure requiring hospitalization. Cardiac death was deﬁned as
death with documentation of a signiﬁcant arrhythmia, cardiac
arrest, or both, or death attributable to congestive heart failure
or myocardial infarction in the absence of any other precip-
itating factors. A sudden unexpected death outside of the
hospital and without an autopsy was attributed to a cardiac
cause. ACS (unstable angina, acute myocardial infarction) was
deﬁned using the standard criteria of history, ECG, and cardiac
enzyme levels. In cases of multiple cardiac events, only the
ﬁrst event was used as the end point of follow-up. Elective
revascularization procedures during follow-up were not con-
sidered to be cardiac events because the decision for coronary
angioplasty might have been subjective.
Statistical Analyses
Continuous variables with normal distributions are
expressed as means ± SD. The low- and high-risk groups
were compared using the independent t test and chi-squared
test. Survival curves were derived by the Kaplan-Meier
method, and the differences between survival curves were
compared using the log-rank test. The multivariate Cox
proportional hazard model was used to evaluate independent
predictors for adverse cardiac outcomes. A sequential Cox
model analysis was performed to assess the incremental
prognostic value of abnormal SPECT results over baseline,
clinical variables, and echocardiographic ﬁndings. The incre-
mental prognostic value was deﬁned by a signiﬁcant increase
in the global chi-square, using the following variables in the
global chi-squared test: age, gender, diabetes, smoking, prior
history of CAD (baseline model), EF, LVH (baseline plus 2D
echocardiography model), perfusion defect, SSS, and SDS
(baseline plus 2D echocardiography plus SPECT model). The
Figure 1. Study ﬂow diagram. From January 2005 to April 2009, 329 ESRD patients started
dialysis and 215 included in our study. *High-risk group was deﬁned as patients[50 years of age,
diabetes [10 years, a prior history of CAD or an abnormal electrocardiogram (excluding LV
hypertrophy and electrolyte imbalance), decreased LV ejection fraction (LVEF)\40% or regional
wall motion abnormality (RWMA) on echocardiography, and having 2 or more traditional CAD
risk factors. ESRD, end-stage renal disease; F/U, follow-up; ECG, electrocardiography; CAG,
coronary angiography; CAD, coronary artery disease; CABG, coronary artery bypass graft; PCI,
percutaneous coronary intervention.
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subgroup of patients (n = 52) underwent CAG. With the
probability data generated by logistic regression analysis, the
methods of Hanley and McNeil were used to generate the areas
under the receiver operating characteristics (ROC) curves for
the baseline clinical model, the baseline plus 2D echocardi-
ography model, and the baseline plus 2D echocardiography
plus SPECT model. The pre- and post-test odds for cardiac
events were calculated using the following formula: post-test
odds = pre-test odds 9 likelihood ratio, where odds = prob-
ability/(1 - probability), and likelihood ratio = sensitivity/
(1 - sensitivity). All data were analyzed using SPSS 18.0
software. Statistical signiﬁcance was deﬁned as P\.05.
RESULTS
Baseline Characteristics
The study population consisted of 215 ESRD
patients with a mean (±SD) age of 57.1 (±14.3) years
(range 21-88 years). Among these, 75 were high-risk
patients with perfusion defects on SPECT, 90 were high-
risk patients without perfusion defects, and 50 were low-
risk patients (Figure 1). Of the 75 high-risk patients with
perfusion defects, 52 (69.3%) underwent CAG, and 36 of
these showed signiﬁcant CAD with the presence of one-
vessel, two-vessel, three-vessel, and left main CAD in 11
(30.6%), 14 (38.9%), 9 (25.0%), and 2 (5.6%) patients,
respectively. For the 23 (30.7%) high-risk patients with
perfusion defects patients who did not undergo CAG, 10
cases were according to the physician’s decision, and 13
cases were due to the patient’s refusal (poor socioeco-
nomic status, n = 6; deprived of family support, n = 7).
The demographic characteristics and risk factors for
CAD are summarized in Table 1. Patients in the high-
risk group were signiﬁcantly older and had higher
prevalence of smoking, diabetes, and hypertension
(P\.001) compared with the low-risk patients. A
signiﬁcantly elevated serum C-reactive protein level
was also observed in the high-risk group (P = .012). In
contrast, except for a history of ischemic heart disease
(IHD), the demographic and risk factor characteristics
were similar between the high-risk patients with and
without perfusion defects. The baseline electrocardio-
graphic and echocardiographic characteristics of both the
groups are shown in Table 2. Compared with subjects in
the low-risk group, the high-risk patients had signiﬁ-
cantly higher rates of LVH, RWMA, and increased
pulmonary pressure, whereas LV systolic function was
lower in the high-risk patients (LVEF 53.7% ± 10.9% vs
58.8% ± 8.4%, low vs high risk; P = .002). Among the
high-risk patients, those with perfusion defects showed
signiﬁcantly lower LVEF, a higher rate of RWMA, and
increased SSS, SRS, and SDS compared with those
without perfusion defects.
Cardiac Events and Survival Analysis
During the follow-up period (mean 50.1 ± 20.9
months; median 47.1 months; range 15.0-87.3 months),
51 patients (30.9%) in the high-risk group experienced
adverse cardiac events, whereas only 2 (4.0%) in the
low-risk group experienced cardiac events, at 10.0 and
34.5 months, respectively. The overall rate of cardiac
events per person-year of follow-up was 15.0% in the
high-risk group with perfusion defects, 4.5% in the high-
risk group without perfusion defects, and 1.2% in the
low-risk group. More detailed cardiac event rates
according to CAG in high-risk patients with perfusion
defects are described in Supplemental Table 1.
As shown in Table 3, increasing age (P = .006),
female gender (P = .016), diabetes (P = .005), RWMA
(P = .003), LVEF (P\.001), and abnormal perfusion
defect (P\.001) predicted cardiac events in the uni-
variate analysis. In the multivariate Cox analysis,
diabetes [hazard ratio (HR) 2.29; 95% conﬁdence
interval (CI) 1.02-5.17; P = .045], a reversible perfu-
sion defect (HR 2.24; 95% CI 1.19-4.22; P = .012), and
LVEF (HR 0.96; 95% CI 0.94-0.99; P = .013) were
independent predictors. Replacing the reversible perfu-
sion defect with any perfusion defect (reversible, ﬁxed,
and mixed) gave similar results (HR 2.11; 95% CI 1.05-
4.24; P = .035). And a 1% increase of LVEF was
associated with 4% reduction of cardiac event rate
Figure 2A shows the Kaplan-Meier estimates for the
occurrence of cardiac events in each group. The risk for
adverse cardiac events was signiﬁcantly higher in high-
risk patients with perfusion defects than in high-risk
patientswithoutperfusiondefects(HR3.28;95%CI1.79-
5.99; P\.001) and low-risk patients (HR 17.56; 95% CI
4.20-73.55; P\.001), emphasizing the importance of
identifying a perfusion defect on SPECT analysis. As
shown in Figure 2B, the presence of signiﬁcant CAD was
associated with increased risk for cardiac events in high-
risk patients (HR 1.94; 95% CI 1.38-2.71; P\.001).
Among the 36 patients with signiﬁcant CAD, 23
(63.9%) were treated with coronary revascularization
therapy (6 by coronary artery bypass graft surgery, 17 by
percutaneous coronary interventions), whereas 13
patients (36.1%) refused coronary revascularization
therapy and were treated medically only. Of the 23
subjects with revascularization, 11 (47.8%) experienced
adverse cardiac events within a mean duration of 38.2 ±
23.1 months, and there were 4 (17.4%) cardiac deaths.
Of the 13 patients who refused coronary revasculariza-
tion therapy, 9 (69.2%) developed adverse cardiac events
within 31.7 ± 19.1 months, and 3 (23.1%) died. As
presented in Figure 3, patients who had signiﬁcant CAD
had a signiﬁcantly higher rate of cardiac events com-
pared with patients having insigniﬁcant or normal CAD
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received only medical treatment appeared to have a
higher rate of cardiac events, revascularization therapy
did not improve the cardiac event-free survival rate (HR
0.62; 95% CI 0.26-1.52; P = .296).
The Incremental Value of SPECT
in High-Risk Group
Further analyses assessed the incremental value of
the SPECT in the high-risk group. For prediction of
cardiac events, three analyses were performed: (1)
baseline (clinical data only), (2) baseline plus 2D
echocardiography, and (3) baseline plus 2D echocardi-
ography plus SPECT. Figure 4 shows the incremental
prognostic values from the global chi-square (upper) and
ROC (lower) analyses. Compared with the baseline
model, the addition of 2D echocardiography data sig-
niﬁcantly improved the prediction of cardiac events
(global chi-square = 29.3, P = .002), and the inclusion
of SPECT data further improved the prognostic value,
increasing the global chi-square value to 40.5
(P\.001). Similarly, the area under the ROC curve
(AUC) of baseline plus 2D echocardiography plus
SPECT data (AUC = 0.829) was signiﬁcantly larger
than that of baseline (AUC = 0.734, P = .001) or
baseline plus 2D echocardiography (AUC = 0.789,
P = .048). The addition of SPECT data provided the
most accurate outcome prediction. The likelihood ratio
of cardiac events for a positive 2D echocardiography
and SPECT was 5.17; the post-test odds was 4.34 with
the mean pre-test probability of CAD was 45.8%.
Table 1. Baseline characteristics of patients (n = 215)
Total Low risk
High risk
Perfusion defect (2) Perfusion defect (1)
Patients, number 215 50 90 (54.5%) 75 (45.5%)
Age (years)* 57.1 ± 14.3 44.1 ± 11.6 59.7 ± 13.1 62.6 ± 12.1
Gender, male, n (%) 113 (52.6) 22 (44.0) 54 (60.0) 37 (49.3)
Smoking, n (%)* 93 (43.2) 10 (20.0) 48 (53.3) 35 (46.7)
BMI (kg/m
2) 23.1 ± 3.6 22.5 ± 3.4 23.5 ± 3.5 23.2 ± 3.8
Diabetes, n (%)* 123 (57.2) 10 (20.0) 58 (64.4) 55 (73.3)
Hypertension, n (%)* 124 (57.7) 18 (36.0) 59 (65.6) 47 (62.7)
MAP (mm Hg) 97.5 ± 13.4 96.5 ± 11.1 99.1 ± 15.2 96.5 ± 11.1
Type of dialysis
Hemodialysis 151 (70.2) 31 (62.0) 70 (77.8) 50 (66.7)
Peritoneal dialysis 64 (29.8) 19 (38.0) 20 (22.2) 23 (33.3)
Cause of ESRD*
Diabetic 122 (56.7) 15 (30.0) 57 (63.3) 50 (66.7)
Hypertensive 38 (17.7) 9 (18.0) 17 (18.9) 12 (16.0)
Glomerulonephritis 26 (12.1) 17 (34.0) 6 (6.7) 3 (4.0)
Others 29 (13.5) 9 (14.0) 10 (11.0) 10 (13.3)
Previous heart disease*
, 
IHD with angioplasty 14 (6.5) 0 (0.0) 5 (5.5) 9 (12.0)
IHD with bypass surgery 3 (1.4) 0 (0.0) 0 (0.0) 3 (4.0)
IHD with medical therapy 9 (4.3) 0 (0.0) 3 (3.4) 6 (7.9)
Congestive heart failure 6 (2.8) 1 (2.0) 2 (2.2) 3 (4.0)
CRP (mg/L)* 5.1 (1.0–37.10) 3.2 (1.0–27.7) 5.6 (1.0–26.10) 6.1 (1.0–37.10)
Medications, n (%)
Aspirin* 119 (55.3) 10 (20.0) 51 (56.7) 58 (77.3)
ACEi/ARBs* 165 (76.7) 31 (62.0) 72 (80.0) 62 (82.7)
b-Blockers 103 (47.9) 25 (50.0) 38 (42.2) 40 (53.3)
Statins* 87 (40.5) 16 (32.0) 36 (40.0) 35 (46.7)
BMI, Body mass index; MAP, mean arterial pressure; ESRD, end-stage renal disease; IHD, ischemic heart disease; CRP, C-reactive
protein; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
* P\.05 between the high- and the low-risk groups.
  P\.05 between patients without and with perfusion defect among the high-risk patients.
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In this study, we found that (1) more than 75% of
ESRD patients could be classiﬁed in a high-risk group
based on clinical and echocardiographic ﬁndings at the
start of dialysis; (2) among the high-risk patients, 45.5%
showed perfusion defects on gated SPECT, and it was a
strong predictor of adverse cardiac mortality; and (3)
coronary revascularization therapy in asymptomatic
ESRD patients was not signiﬁcantly associated with an
improved cardiac event-free survival rate. Gated SPECT
analysis may be a useful tool in selecting patients at high
risk for adverse cardiac outcomes and in choosing a
therapeutic option.
SPECT, with its high diagnostic and prognostic
accuracy,
8,9 is one of the most extensively validated and
commonly employed methods in various subsets of
populations, including patients with diabetes,
10 patients
after myocardial infarction and revascularization ther-
apy,
9,11,12 patients with CKD,
13-15 patients with
ESRD,
16-18 and renal transplantation candidates.
19-21
Table 2. Assessment of baseline cardiac status and clinical outcomes
Total
(n 5 215)
Low risk
(n 5 50)
High risk
Perfusion
defect (2)
(n 5 90)
Perfusion
defect (1)
(n 5 75)
Electrocardiography, n (%)
LVH* 140 (65.1) 22 (44.0) 64 (71.1) 54 (72.0)
Pathologic Q wave*
,  29 (13.5) 3 (6.0) 10 (11.1) 16 (21.3)
ST wave abnormality 121 (56.3) 25 (50.0) 52 (57.8) 44 (58.7)
Echocardiography
LVEF*
,  55.0 ± 10.6 58.8 ± 8.4 56.7 ± 9.6 50.1 ± 11.4
RWMA, n (%)*
,  37 (17.2) 0 (0.0) 14 (15.6) 23 (30.6)
LV geometry*
Normal 72 (33.5) 27 (34.0) 25 (27.8) 20 (26.7)
Concentric hypertrophy 113 (52.6) 17 (34.0) 52 (57.8) 44 (58.7)
Eccentric hypertrophy 25 (11.6) 6 (12.0) 9 (10.0) 10 (13.3)
Concentric remodeling 5 (2.3) 0 (0.0) 4 (4.4) 1 (1.3)
Pulmonary hypertension*
, 
None 177 (82.3) 46 (92.0) 80 (88.9) 51 (68.0)
Mild 16 (7.4) 2 (4.0) 3 (3.3) 11 (14.7)
Moderate to severe 22 (10.2) 2 (4.0) 7 (7.8) 13 (17.3)
SPECT
EF at stress
  – – 55.9 ± 11.5 49.0 ± 9.7
TID – – 1.04 (0.68–1.35) 1.08 (0.22–1.64)
SSS
  – – 0 (0–8) 4 (0–33)
Normal (0–4), n (%) 81 (90.0) 47 (62.7)
Mild (4–8), n (%) 6 (6.7) 12 (16.0)
Moderate–severe (C9), n (%) 3 (3.3) 16 (21.3)
SRS
  – – 0 (0–3) 2 (0–21)
SDS
  – – 0 (0–4) 2 (0–12)
Cardiac events*
, , n (%)
Total 53 (24.7) 2 (4.0) 15 (16.7) 36 (48.0)
Nonfatal ACS 30 (14.0) 1 (2.0) 7 (7.8) 22 (29.3)
Cardiac death 19 (8.8) 1 (2.0) 7 (7.8) 11 (14.7)
ADHF 4 (1.9) 0 (0.0) 1 (1.1) 3 (4.0)
LVH, Left ventricular hypertrophy; LVEF, left ventricular ejection fraction; RWMA, regional wall motion abnormality; SPECT, single-
photon emission computed tomography; TID, transient ischemic dilatation; SSS, summed stress score; SRS, summed rest score;
SDS, summed difference score; ACS, acute coronary syndrome; ADHF, acute decompensated heart failure.
* P\.05 between the high- and the low-risk groups.
  P\.05 between patients without and with perfusion defect among the high-risk patients.
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tomatic patients than in those with active symptoms. The
2003 ACC/AHA/ASNC guidelines for the clinical use of
cardiac radionucleotide imaging suggested that SPECT
may be helpful in some asymptomatic high-risk
patients.
22 According to the most recent 2009 guidelines,
the use of SPECT is considered to be appropriate and
necessary in asymptomatic patients at high-risk for
CAD.
23
Here, we determined the level of cardiac risk based
on traditional CAD risk factors, including electrocar-
diographic and echocardiographic features, and based on
the result of stress/rest gated SPECT, especially for
high-risk patients. Consistent with previous data,
10,13,15
our study found that patients with perfusion defects and
increased SSS (C4) had a 3.3- and 2.1-fold increase in
relative risk for cardiac events compared with patients
without perfusion defects, even in the same high-risk
group. Considering that there were minimal differences
in baseline clinical parameters between patients with
and without perfusion defects, abnormal SPECT ﬁnd-
ings may have signiﬁcant implications in cardiac risk
stratiﬁcation. Multivariate Cox analysis also demon-
strated the importance of determining perfusion defects,
as well as reversible perfusion defect, for the prediction
of long-term cardiac risk. Furthermore, this study
conﬁrmed the beneﬁt of SPECT over clinical and
echocardiographic variables; adding the SPECT results
Table 3. Signiﬁcant predictors for cardiac events
Variables
Univariate analysis
Multivariate
analysis*
Multivariate
analysis**
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age (per 1 year) 1.03 (1.01–1.06) .006 1.03 (0.99–1.05) .065 1.02 (0.99–1.05) .070
Male (vs female) 0.50 (0.30–0.88) .016 0.64 (0.36–1.15) .134 0.62 (0.35–1.12) .115
Diabetes (vs non–diabetes) 3.14 (1.41–6.97) .005 2.29 (1.02–5.17) .045 2.31 (1.02–5.22) .044
Prior IHD 2.43 (1.33–4.45) .004 – – – –
hs-CRP (per 1 mg/L) 1.05 (1.01–1.09) .010 – – – –
RWMA (vs normal) 2.32 (1.32–4.08) .003 – – – –
LVH (vs normal) 1.64 (0.85–3.16) .140 – – – –
LVEF (per 1%) 0.95 (0.93–0.98) \.001 0.96 (0.94–0.99) .013 0.97 (0.94–0.99) .025
Perfusion defect (vs normal) 3.28 (1.79–6.00) \.001 2.24 (1.19–4.22) .012 2.11(1.05–4.24) .035
SSS C4 (vs\4) 1.68 (0.92–3.10) .081 – – – –
HR, Hazard ratio; CI, conﬁdence intervals; IHD, ischemic heart disease; hs-CRP, high-sensitivity C-reactive protein; RWMA,
regional wall motion abnormality; LVH, left ventricular hypertrophy; LVEF, left ventricular ejection fraction; SSS, summed stress
score.
* Adjusted with age, gender, diabetes, LV ejection fraction, and reversible perfusion defect.
** Adjusted with age, gender, diabetes, LV ejection fraction, and any type of perfusion defect (reversible, ﬁxed, and mixed).
Figure 2. Kaplan-Meier estimates for the occurrence of cardiac events in low (n = 50)- and high
(n = 165)-risk patients. Among high-risk patients, the presence of perfusion defect was closely
associated with adverse cardiac outcomes (HR 3.16; 95% CI 1.65-6.04, P = .001) (A) and the
presence of CAD signiﬁcantly increased the risk of cardiac events (HR 1.94 95% CI 1.38-2.71,
P\.001) (B).
444 J.-K. Kim et al Journal of Nuclear Cardiology
Role of gated SPECT in dialysis patients May/June 2012to clinical and/or echocardiographic data provided
signiﬁcant incremental prognostic value for the predic-
tion of adverse cardiac outcomes. These ﬁndings support
the widely accepted idea that the diagnostic and prog-
nostic accuracy of SPECT is greater than that of clinical
or echocardiographic data, and even that of CAG in risk
stratiﬁcation of CAD. In 2009, Gimelli et al
8 evaluated
the efﬁcacy of stress/rest gated SPECT and demon-
strated that myocardial perfusion abnormalities
identiﬁed by gated SPECT may be the best predictor
of cardiac event-free survival, even when compared with
an extensive diagnostic CAD work-up that included
clinical, echocardiographic, and angiographic analyses.
On the other hand, compared with our results, a
recently published study from the Netherlands reported
seemingly contradictory results with renal transplant
patients.
24 Aalten et al reported that the incidence of
signiﬁcant cardiac ischemia was low (6.6%) and signif-
icant beneﬁt could not be observed with a preoperative
cardiac assessment program for adverse cardiac out-
comes, especially early cardiac events (B30 days of
transplantation). However, there are important differ-
ences between these two studies. Aalten et al evaluated
the beneﬁt of a cardiac screening test in subjects limited
to renal transplant candidates among a relatively young
and healthy population. Their patient group had a
younger mean age (50.8 vs 61.0 years), a lower
percentage of diabetes (8.8% vs 68.5%), and a lower
rate of cardiac disease history (11.2% vs 17.5%)
compared with our patients. This may explain the
relatively low rate of signiﬁcant ischemia on a non-
invasive stress test (3.6%) and low rate of perioperative
cardiac events observed in their study. Furthermore, our
study evaluated the long-term cardiac event rate (over
4 years), whereas their study evaluated short-term car-
diac events (B30 days of transplantation) and did not
address long-term beneﬁts. Similar results were also
shown by Hage et al in 2007.
25 With 3,698 kidney
transplant candidate, they evaluated all-cause mortality
during a mean follow-up of 2.5 years and reported that
the presence and the severity of CAD was not predictor
for survival, but LV ejection fraction was the best
predictor for death. However, their patients were at
relatively lower risk and had more favorable baseline
characteristics, too. Thus, the incidence of abnormal
ﬁndings on MPI was only 19%, and three-vessel CAD
was found only in 2% of patients, while 52.7% and
25.0% of our patients showed abnormal MPI results and
three-vessel CAD, respectively. Nevertheless, the sig-
niﬁcant role of LV ejection fraction for predicting
mortality was in good accordance with our data.
Our study did not demonstrate a reduced risk for
cardiac events in asymptomatic patients with signiﬁcant
CAD after coronary revascularization, compared with
those who received optimal medical therapy alone (HR
0.62; 95% CI 0.26-1.52; P = .296). However, this
ﬁnding should be interpreted with caution because the
Figure 3. Kaplan-Meier analysis of the cardiac event rate in
high-risk patients with signiﬁcant CAD. Revascularization
therapy did not improve cardiac events-free survival (HR 0.62,
95% CI 0.26-1.52; P = .296).
Figure 4. Incremental prognostic value of SPECT over base-
line (clinical only) and baseline plus 2D echocardiographic
variables; upper global chi-square, lower ROC curve analysis.
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sample size. Nevertheless, the optimal CAD therapy in
this population remains uncertain and the beneﬁt of pre-
emptive coronary revascularization therapy (percutane-
ous coronary intervention or coronary artery bypass
graft) at the start of dialysis on the long-term outcome is
unclear.
26,27 Previously, clinicians were reluctant to
perform early revascularization therapy in this popula-
tion for fear of the complete loss of residual renal
function as a result of contrast nephropathy or a higher
rate of procedure-related complications.
26 Moreover,
according to the limited data available, ESRD is asso-
ciated with a higher rate of stent restenosis following
percutaneous coronary intervention.
28 However, recent
advances in surgery and percutaneous coronary inter-
vention as well as additional adjunctive medical
therapies have lowered the complication rate and stent
restenosis rate in this population.
27,29 Reddan et al
30
reported that revascularization therapy using percutane-
ous coronary intervention or coronary artery bypass graft
improved the survival of CKD patients. Moroi et al
31 also
evaluated the effects of revascularization in patients with
stable IHD and showed a beneﬁt for patients with
moderate to severe ischemia. Nevertheless, the optimal
timing for revascularization therapy has not yet been
established. In some ways, coronary revascularization
performed at the initiation of dialysis may already be too
late to improve cardiac outcomes. However, considering
the risk for contrast nephropathy in non-dialysis CKD
patients,
14 cardiac revascularization at the initiation of
dialysis may be optimal. Additional long-term, well-
designed, large-scale comparative trials are needed.
This study has several limitations. First, the predic-
tive role of SPECT was evaluated in only a selected
high-risk group of ESRD patients at baseline. SPECT
imaging has been shown to be inappropriate for low-risk
patients, as no proven clinical value of SPECT has been
demonstrated in these patients.
23 However, in our study,
two patients in the low-risk group experienced cardiac
events. The usefulness of gated SPECT in low-risk
patients should be further evaluated in a larger cohort.
Second, this study was a non-randomized and non-
comparative study, and thus we could not demonstrate
the beneﬁt of our cardiac risk assessment protocol on
cardiovascular mortality, compared with the routine
screening test recommended by KDOQI guidelines.
Third, a substantial portion of the patients (13/36,
36.1%) did not undergo CAG, despite reversible perfu-
sion defects on SPECT. In practice, it was impossible to
perform CAG in these patients because the patients or
their families refused to provide the required signed
consent. At last, about 10% of patients (n = 23) lost to
follow-up during study period. Therefore, we could not
predict future cardiac event rate more accurately.
In conclusion, baseline cardiac risk stratiﬁcation
based on gated SPECT analysis may be useful for the
prediction of cardiac mortality in asymptomatic ESRD
patients. It may also provide prognostic information, in
addition to clinical and echocardiographic data, for
cardiac risk stratiﬁcation, particularly among high-risk
patients starting dialysis. More detailed cardiac risk
assessment methods using non-invasive imaging param-
eters such as coronary calcium scores, carotid intima-
media thicknesses, or ankle brachial indexes are needed
for further stratiﬁcation of high-risk patients.
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